<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; } </style>

United States // News Releases

News Releases

INVESTOR RESOURCES
Filter Releases
 
News Releases
Date Title and Summary View
Mar 16, 2011
IRVINE, Calif., March 16, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced the filing of its annual report on Form 10-K and certain revisions to its previously reported unaudited fourth quarter and full year 2010 financial results. Upon finalization of the purch...
Mar 7, 2011
IRVINE, Calif., March 7, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the ROTH 23rd Annual OC Growth Stock Conference in Laguna Niguel, CA. Event: ROTH 23rd Annual OC G...
Feb 22, 2011
IRVINE, Calif., Feb. 22, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2010. John McDermott, Endologix President and Chief Executive Officer, said, "We made tremendous progress in all areas...
Feb 15, 2011
IRVINE, Calif., Feb. 15, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the presentation of the initial clinical results from the PEVAR Trial at the 2011 iCON (International Congress of Endovascular Specialists) annual meeting in Scottsdale, Arizona. Among 33 pat...
Jan 31, 2011
IRVINE, Calif., Jan. 31, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the publication of favorable clinical results for the Nellix technology for the endovascular repair of abdominal aortic aneurysm (EVAR).  The peer-reviewed article reported initial results fr...
Jan 20, 2011
IRVINE, Calif., Jan. 20, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2010 financial results, which will take place on Tuesday, February 22, 2011 after the close of the market. Endologix wil...
Jan 4, 2011
IRVINE, Calif., Jan. 4, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Event: 29th Annual J.P. Mor...
Dec 20, 2010
IRVINE, Calif., Dec. 20, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that Guido Neels, Managing Director at Essex Woodlands Health Ventures, has joined the Endologix Board of Directors. Essex Woodlands was the majority shareholder of Nellix Inc, whic...
Dec 13, 2010
IRVINE, Calif., Dec. 13, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc.  Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to add...
Nov 29, 2010
IRVINE, Calif., Nov. 29, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences.  The first presentation will be at the 22nd Annual Piper Ja...
Nov 12, 2010
IRVINE, Calif., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that a podium presentation on the Company's Ventana™ fenestrated stent graft will be given at the VEITHsymposium 2010 in New York by Daniel G. Clair, MD, Chairman, Cleveland Clinic ...
Nov 10, 2010
IRVINE, Calif., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences.  The first presentation will be at the Lazard Capital Marke...
Nov 3, 2010
IRVINE, Calif., Nov. 3, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that the Company will host a physician conference call on Thursday, November 11, 2010 at 1:00 p.m. ET / 10:00 a.m. PT. to provide further information on the EVAR technology developed...
Nov 2, 2010
IRVINE, Calif., Nov. 2, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the first clinical implant of the Company's Ventana(TM) fenestrated stent graft at Auckland City Hospital in Auckland, New Zealand. The procedure was performed by Andr...
Oct 27, 2010
IRVINE, Calif., Oct 27, 2010 /PRNewswire via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2010. John McDermott, Endologix President and Chief Executive Officer, said, "Our strong results we...
= add release to Briefcase